Drug intelligence / Profile preview

MY-008

Development stage: Phase 3
Lead developer: Wuhan Createrna Science and Technology
Modality: Small Molecules
Administration: Oral

Overview

MY-008 is an orally administered small molecule drug under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (Berger’s Disease). It acts as an **inhibitor** of **complement factor B (CFB)**, a key component in the alternative pathway of the complement system, which plays a role in immune-mediated diseases. The drug is being developed by Wuhan Createrna Science and Technology, with origins from Shanghai Meiyue Biotech Development. As of April 2025, it has reached Phase 3 clinical trials for its lead indications[1][2][3][4].

Other names: MY008211AMY-008211AMY 008211A

Targets

CFB (Complement Factor B)

Beyond the preview

Go deeper on MY-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MY-008.

Explore the full profile